TY - JOUR
T1 - Novel Therapies for Lipoprotein(a)
T2 - Update in Cardiovascular Risk Estimation and Treatment
AU - Wulff, Anders Berg
AU - Nordestgaard, Børge G
AU - Langsted, Anne
N1 - © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2024/4
Y1 - 2024/4
N2 - Purpose of Review: Lipoprotein(a) is an important causal risk factor for cardiovascular disease but currently no available medication effectively reduces lipoprotein(a). This review discusses recent findings regarding lipoprotein(a) as a causal risk factor and therapeutic target in cardiovascular disease, it reviews current clinical recommendations, and summarizes new lipoprotein(a) lowering drugs. Recent Findings: Epidemiological and genetic studies have established lipoprotein(a) as a causal risk factor for cardiovascular disease and mortality. Guidelines worldwide now recommend lipoprotein(a) to be measured once in a lifetime, to offer patients with high lipoprotein(a) lifestyle advise and initiate other cardiovascular medications. Clinical trials including antisense oligonucleotides, small interfering RNAs, and an oral lipoprotein(a) inhibitor have shown great effect on lowering lipoprotein(a) with reductions up to 106%, without any major adverse effects. Summary: Recent clinical phase 1 and 2 trials show encouraging results and ongoing phase 3 trials will hopefully result in the introduction of specific lipoprotein(a) lowering drugs to lower the risk of cardiovascular disease.
AB - Purpose of Review: Lipoprotein(a) is an important causal risk factor for cardiovascular disease but currently no available medication effectively reduces lipoprotein(a). This review discusses recent findings regarding lipoprotein(a) as a causal risk factor and therapeutic target in cardiovascular disease, it reviews current clinical recommendations, and summarizes new lipoprotein(a) lowering drugs. Recent Findings: Epidemiological and genetic studies have established lipoprotein(a) as a causal risk factor for cardiovascular disease and mortality. Guidelines worldwide now recommend lipoprotein(a) to be measured once in a lifetime, to offer patients with high lipoprotein(a) lifestyle advise and initiate other cardiovascular medications. Clinical trials including antisense oligonucleotides, small interfering RNAs, and an oral lipoprotein(a) inhibitor have shown great effect on lowering lipoprotein(a) with reductions up to 106%, without any major adverse effects. Summary: Recent clinical phase 1 and 2 trials show encouraging results and ongoing phase 3 trials will hopefully result in the introduction of specific lipoprotein(a) lowering drugs to lower the risk of cardiovascular disease.
KW - Cardiovascular Diseases/drug therapy
KW - Heart Disease Risk Factors
KW - Humans
KW - Lipoprotein(a)/drug effects
KW - Oligonucleotides, Antisense/therapeutic use
KW - Risk Factors
UR - http://www.scopus.com/inward/record.url?scp=85184171948&partnerID=8YFLogxK
U2 - 10.1007/s11883-024-01192-9
DO - 10.1007/s11883-024-01192-9
M3 - Review
C2 - 38311667
SN - 1523-3804
VL - 26
SP - 111
EP - 118
JO - Current Atherosclerosis Reports
JF - Current Atherosclerosis Reports
IS - 4
ER -